Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders

Stopped We are doing a clinical study of Baritinib in Neuromyelitis Optica Spectrum Disorders, similar to this one, so the study was withdrawn.

Conditions

• Neuromyelitis Optica Spectrum Disorder Relapse

Interventions

• DRUG: Ruxolitinib

Sponsor

Tianjin Medical University General Hospital